九洲藥業(603456.SH):擬通過增資擴股方式向九洲生物引入員工持股平台
格隆匯3月18日丨九洲藥業(603456.SH)公佈,公司於2022年3月18日召開的第七屆董事會第十七次會議審議通過了《關於全資子公司實施增資擴股並引入員工持股平台的議案》,為進一步加快九洲生物的業務發展,優化九洲生物治理結構,穩定和吸引人才,充分調動管理團隊和核心骨幹員工的積極性,公司擬通過增資擴股方式向九洲生物引入員工持股平台。
員工持股平台以貨幣方式對九洲生物合計增資人民幣2914.47萬元認購九洲生物新增的1833萬元註冊資本,差額部分計入九洲生物的資本公積。基於對九洲生物長遠發展的綜合考慮,浙江九洲藥業股份有限公司放棄此次增資的優先認購權。
此次增資完成後,公司持有九洲生物5500萬元註冊資本,持股佔比75%;員工持股平台合計持有九洲生物1833萬元註冊資本,持股佔比25%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.